T lymphocytes export proteasomes by way of microparticles: a possible mechanism for generation of extracellular proteasomes

Isabel Bochmann a, Frédéric Ebstein a, Andrea Lehmann a, Jeremias Wohlschlaeger b, Stephan Urs Sixt c, Peter-Michael Kloetzela, Burkhardt Dahlmann a, *

a Institut für Biochemie, Charité-Universitätsmedizin Berlin, Berlin, Germany
b Institut für Pathologie and Neuropathologie, Universität Duisburg-Essen, Essen, Germany
c Klinik für Anaesthesiologie, Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany

Received: April 30, 2013; Accepted: September 10, 2013

Abstract

The 20S proteasome is almost exclusively localized within cells. High levels of extracellular proteasomes are also found circulating in the blood plasma of patients suffering from a variety of inflammatory, autoimmune and neoplastic diseases. However, the origin of these proteasomes remained enigmatic. Since the proteome of microparticles, small membrane enclosed vesicles released from cells, was shown to contain proteasomal subunits, we studied whether intact proteasomes are actively released into the extracellular space. Using human primary T lymphocytes stimulated with CaCl2 and the calcium ionophore A23187 to induce membrane blebbing we demonstrate that microparticles contain proteolytically active 20S proteasomes as well as the proteasome activator PA28 and subunits of the 19S proteasome regulator. Furthermore, our experiments reveal that incubation of in vitro generated T lymphocyte-microparticles with sphingomyelinase results in the hydrolysis of the microparticle membranes and subsequent release of proteasomes from the vesicles. Thus, we here show for the first time that functional proteasomes can be exported from activated immune cells by way of microparticles, the dissolution of which may finally lead to the generation of extracellular proteasomes.

Keywords: proteasome ● circulating ● extracellular ● microparticles ● sphingomyelinase ● T lymphocytes

Introduction

Extracellular proteasomes circulating in blood plasma (circulating proteasomes) are potential diagnostic biomarkers for various malignancies like systemic lupus erythematoses (SLE) [1], melanoma [2], multiple myeloma [3], epithelial ovarian cancer [4] and hepatocellular carcinoma [5, 6]. Clear correlations were found to exist between the plasma level of extracellular proteasomes and the malignant transformation of cirrhotic liver cells [6] as well as residual tumour mass after therapy in patients suffering from epithelial ovarian cancer [4].

The proteasome catalyses the degradation of intracellular proteins and is involved in vital functions like cell cycle progression, differentiation, immune defence and the stress response [7, 8]. The barrel-shaped 20S proteasome is composed of four stacked, seven-membered rings, two inner β and two outer α rings. The α rings provide contact to 19S regulators or to the proteasome activator PA28 thus forming 26S proteasomes (19S-20S), 30S proteasomes (19S-20S-19S), PA28-20S proteasome-complexes or hybrid proteasomes (PA28-20S-19S), respectively. The β rings contain the three proteolytically active subunits with β1 exhibiting caspase-like, β2 trypsin-like and β5 chymotrypsin-like activity. Cytokines like interferon-γ induce the expression of the immuno-subunits β1i (LMP2), β2i (MECL1) and β5i (LMP7), which replace the standard-subunits β1, β2 and β5 resulting in the biogenesis of immuno-proteasomes [7, 8]. Immunoproteasomes are constitutively generated by cells involved in the immune response like spleenocytes, thymocytes, dendritic cells and others [9].

Circulating proteasomes from human plasma are proteolytically active 20S proteasomes [10]. They were also detected in the lung epithelial lining fluid of patients with acute respiratory distress syndrome [11] and in cerebrospinal fluid [12]. Apart from their importance as diagnostic biomarkers extracellular proteasomes may also exert various extracellular functions [13, 14]. However, so far the mechanisms by which proteasomes are released into the extracellular space...
remained obscure [15]. Although a passive efflux of proteasomes as a result of cell death occurring in the course of various diseases cannot be excluded, several observations argue in favour of a specifically directed mechanism [13, 15].

Proteasomal subunits contain no signal sequence for export via the classic secretory pathway. Therefore, alternative secretion mechanisms might be responsible for proteasome release to the extracellular environment [16–18], e.g. secretory lysosomes and plasma-membrane-residing transporters. But so far there exists no evidence for a proteasome-interacting transporter at the plasma membrane. Another alternative export pathway releases exosomes, which are 50–100 nm vesicular structures. Finally, a membrane blebbing pathway was described whereby cytoplasmic content is entrapped in protrusions of the membrane, which are then directly shed as vesicles (microparticles) of heterogeneous size (0.1–1 μm) from the plasma membrane of activated cells. During the last decade evidence was provided that microparticles (MP) can act as messengers between cells since they transport a variety of molecules [19–22]. Proteomic analyses of microparticles derived from platelets and a T lymphocyte cell line have revealed the presence of subunits of the proteasome, the proteasome activator PA28 and the ubiquitination machinery [23, 24]. By means of immunoelectron microscopy proteasomes were also identified in vesicles in cerebrospinal fluid [12]. Therefore, we investigated whether membrane blebbing and shedding of vesicles as well as their subsequent breakdown may be a mechanism by which proteasomes are released from cells thereby generating extracellular proteasomes.

Materials and methods

Materials

Roswell Park Memorial Institute (RPMI) 1640 medium without phenol red, foetal calf serum (FCS), penicillin/streptomycin, L-glutamine and biocoll reagent were from Biochrom AG (Berlin, Germany). A23187, ethylene glycol tetraacetic acid (EGTA) and sphingomyelinase were purchased from Sigma-Aldrich (Taufkirchen, Germany). Epoxomicin was from Calbiochem (Nottingham, UK). The polyclonal proteasome antibody (PW8155), the monoclonal α6- and β1- and the polyclonal β5-antibodies were from Enzo Life Sciences (Lorrach, Germany). The polyclonal antibodies for β1i/LMP2 and β5i/LMP7 and the monoclonal LFA-1-antibody were from Abcam (Cambridge, UK). The Rpt3 antibody was a kind gift from Claus Hendil (Copenhagen, Denmark). The polyclonal rabbit PA28α antibody was a laboratory stock. The PA28β antibody was from Cell Signalling (Frankfurt, Germany). 20S and 26S proteasome as well as PA28 were prepared from human erythrocytes [25] and 20S proteasome from spleenocytes were from BioMol (Exeter, UK). The TruCounttm tubes, CD3-PE antibody and annexin V-FITC were from BD Biosciences (Heidelberg, Germany). CytoTox One homogenous membrane integrity assay was from Promega (Mannheim, Germany).

Cell culture

T lymphocytes were isolated from buffy coats of healthy donors provided by German Red Cross (Berlin, Germany). They were maintained in RPMI 1640 medium without phenolred supplemented with 10% (v/v) heat-inactivated FCS, 100 U/100 μg/ml penicillin/streptomycin and 2 mM L-glutamine (complete medium) at 37°C in a 5% CO2 atmosphere up to 1 week after isolation. For the experiments 5 × 106 cells were centrifuged (300 × g, 8 min.) and taken up in 6 ml of serum-free or microparticle-free (MP-free) medium. MP-free medium is complete medium supplemented with FCS centrifuged at 100,000 × g over night to remove bovine plasma microparticles.

Isolation of T lymphocytes

Buffy coats were diluted with 0.5–1 volume of RPMI 1640 medium (without supplements) and 40 ml of the cell suspension were covered on 12 ml Biocoll reagent and centrifuged for 30 min. at 20°C (675 × g). Peripheral blood mononuclear cells (PBMCs) remaining in the layer above the Biocoll reagent were isolated and washed three times in RPMI (8 min., 300 × g, 4°C). For separation of monocytes from T and B cells, PBMCs were diluted in RPMI and incubated in cell culture flasks for 3–4 hrs at 37°C in a 5% CO2 atmosphere. Under these conditions monocytes adhere to the cell culture flask and the supernatant contains the T and B lymphocytes. 85% of the isolated cells were CD3-positive T cells as analysed by flow cytometry (data not shown).

Preparation of microparticles

5 × 107 T cells were stimulated with 2 μM A23187 calcium ionophore in serum-free or MP-free medium supplemented with 1 mM CaCl2 [26]. Control cells were stimulated with DMSO or DMSO plus 1 mM CaCl2 at 37°C in a 5% CO2 atmosphere for 45 min., respectively. The medium containing cells and microparticles was subjected to differential centrifugation at 470 × g for 5 min. at 4°C to remove the cells. The supernatant was transferred to a second centrifugation (1400 × g) for 4 hrs at 37°C to remove larger debris. To isolate microparticles, the supernatant was centrifuged at 100,000 × g for 20 min. at 4°C. The centrifugation step was repeated two times if washing of the microparticles with PBS was required. The effect of Ca2+/A23187 treatment on cell viability was checked by trypan blue staining and LDH release (CytoTox ONE) according to the manufacturer’s protocol.

Quantification of 20S proteasome

Quantification of 20S proteasome was carried out by ELISA after breakdown of the microparticles in PBS supplemented with 1% Tween 20 by repeated freeze-thaw cycles and subsequent centrifugation to remove residual lipids (45 min., 20,000 × g, 4°C). The capturing antibody against the proteasome-subunit α6, dissolved 1 μg/ml PBS, was bound to an ELISA plate over night at 4°C. After washing with PBST (PBS containing 0.2% Tween 20), the plate was blocked with 1% albumin fraction V dissolved in PBST for 2 hrs and the washing step was repeated. On each ELISA plate purified erythrocyte 20S proteasome was used as calibration standard. The samples (plasma samples were diluted 1:2) and proteasome standards were detected with a polyclonal antibody to 20S proteasome (dilution 1:1000), the binding of which was photometrically quantified with a peroxidase-coupled rabbit IgG antibody and TMB substrate (BD Biosciences). The detection range was 2–60 ng of proteasome.
Proteasome activity

The proteasome activity was measured by cleavage of fluorogenic peptide-substrates as described elsewhere [10]. T cells or proteasome-containing microparticles and substrates were resuspended or dissolved in TEAD buffer (20 mM Tris-HCl, 1 mM EDTA, 1 mM NaN₃, 1 mM di-thiothreitol; pH 7.5). For detection of the different proteasomal activities fluorogenic peptide substrates Suc-LLVY-AMC (chymotrypsin-like activity), Bz-VGR-AMC (trypsin-like activity) and Z-LLE-AMC (caspase-like activity) (Bachem, Bubendorf, Switzerland) were used at final concentration, Bz-VGR-AMC (trypsin-like activity) and Z-LLE-AMC (caspase-like activity) (Bachem, Bubendorf, Switzerland) were used at final concentrations of 100, 200 and 200 μM, respectively. Proteasome inhibition was performed with 1 μM epoxomicin.

Flow cytometric detection and quantification of microparticles

Microparticles were generated and isolated as described and washed two times in sterile filtered PBS. After the last centrifugation step, the microparticles were suspended in 200 μl sterile-filtered annexin V binding buffer, transferred to Trucount™ tubes and stained with FITC-annexin V. After 15 min. of incubation the samples were diluted by 400 μl annexin V binding buffer and directly analysed with an FACS Calibur flow cytometer (BD Biosciences). The size analysis with Megamix beads was accomplished according to the manufacturer's protocol (Biocytex, Marseille, France).

Western blot analysis

T cells (5 × 10⁷) were stimulated with 1 mM CaCl₂ and 2 μM A23187 calcium ionophore in serum-free medium for 45 min. before cells and microparticles were separated by centrifugation. The pelletted cells were washed with PBS and resuspended in 100 μl of RIPA buffer (10 mM Tris-HCl pH 7.5, 100 mM NaCl, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS) supplemented with Complete protease inhibitor mix (Roche, Basel, Switzerland); the microparticles were suspended in 20–40 μl RIPA buffer. Cells and microvesicles were then disrupted by repeated freeze-thaw cycles and undissolved material precipitated at 20,000 × g for 40 min. at 4°C. The microparticle supernatants were mixed with sample buffer (20 mM Tris-HCl pH 6.8, 10% (w/v) glycerol, 5% β-mercaptoethanol, 2% SDS, 0.05% bromphenol blue) and entirely loaded on the SDS-gel. Protein concentrations were measured in cell lysate by means of BCA assay and equal amounts of protein were subjected to SDS-PAGE (12% w/v). The proteins were immunoblotted and detected by using the ECL Reagent.

Digestion of microparticles with sphingomyelinase

For enzymatic breakdown of microparticles, the isolated microvesicles were resuspended in 10 mM HEPES, pH 7.4, containing 140 mM NaCl, 2.7 mM KCl, 1 mM MgCl₂, 5 mM glucose and 1 mM CaCl₂ and then incubated at 37°C with or without 0.1 U/ml sphingomyelinase from Bacillus cereus [28]. After 1 hr of enzymatic digestion remaining vesicle residues were pelleted at 20,000 × g for 40 min. and the supernatants analysed for 20S proteasomes by ELISA. The membrane fraction was resuspended in RIPA buffer supplemented with complete protease inhibitor cocktail, the membranes were disrupted by repeated freeze-thaw cycles and after centrifugation the supernatant was subjected to SDS-PAGE.

Native PAGE

Microparticles were isolated from 2.5 × 10⁸ T lymphocytes and suspended in a 10:1 (v/v) mixture of TSDG buffer (10 mM Tris-HCl, 25 mM KCl, 10 mM NaCl, 1.1 mM MgCl₂, 0.1 mM EDTA, 1 mM DTT, 2 mM ATP, 10% glycerol, pH 7.2) and native gel loading buffer (5 mM Tris-HCl, 5% glycerol and 0.01% bromphenolblue). Electrophoresis was performed on 3–12% Native PAGE BisTris gels before the proteasomal trypsin-like activity was visualized by substrate overlay with 200 μM Bz-VGR-AMC. Alternatively the proteasomes were analysed by immunoblotting.

Blood collection and microparticle isolation of human plasma

Twenty millilitre peripheral blood was collected from healthy donors with 21-gauge needles in Vacutainer tubes (BD Biosciences) supplemented with citrate. Platelet-free plasma was produced by different centrifugation steps, 500 × g for 10 min and two times at 2000 × g for 30 min. [27]. One millilitre platelet-free plasma was diluted 1:4 (v/v) with PBS and microparticles were isolated at 100,000 × g for 40 min. at 4°C, washed with PBS and collected at 100,000 × g for 20 min. The supernatant fraction was used for the quantification of free plasma proteasomes and the pelleted fraction for vesicle-bound proteasomes. The latter were also analysed by immune blotting.

Statistical analysis

Statistical comparison of two groups of data was done by Student’s t-test or in case of equal variance by Mann–Whitney Rank Sum Test. Error bars display standard error of the mean (±SEM) values. P-values lower than 0.05 were considered statistically significant.

Results

Cellular and vesicular T lymphocyte proteasomes

Microparticles of T lymphocytes and other blood cells were found in blood plasma of healthy individuals and patients suffering from various diseases [28]. We hypothesized that microvesicles may be a source for extracellular proteasomes. To allow comparison of T cell derived proteasomes with those that may be present in T cell derived microvesicles we initially analysed proteasomes in primary T lymphocytes of healthy donors. T cell lysates incubated with proteasome-specific fluorogenic peptide substrates showed all three proteasomal activities. The chymotrypsin- and trypsin-like activities could be inhibited by epoxomicin (P ≤ 0.001 and 0.002, respectively, Fig. 1A). To
Characterization of microparticles shed by activated T lymphocytes

If vesicle shedding by T cells results from cell membrane blebbing, microvesicles are expected to contain proteins originating from their parental cell [28]. Therefore, the vesicular membranes were dissolved by detergents and tested for the presence of a T cell membrane-localized protein, the leucocyte-derived integrin lymphocyte-function associated antigen-1 (LFA-1). Figure 1E clearly revealed the existence of LFA-1 in the vesicle membranes suggesting that membrane blebbing and shedding occurs continuously.

From earlier studies it is known that cells can be activated by the A23187 calcium ionophore and CaCl₂ resulting in an enhanced segregation of microparticles from the plasma membrane [26]. Therefore, we stimulated T lymphocytes with A23187 and CaCl₂ before the vesicle fraction was isolated and analysed by flow cytometry (Fig. 2). During the shedding process, the parental cells lose their membrane symmetry at vesicle exit sites. This leads to exposure of phosphatidylserine residues to the outer leaflet of the plasma membrane [28] thereby allowing the specific binding of annexin V to phosphatidylserine. Together with the particle size this feature can serve as a marker to differentiate microparticles from other particulate structures [29]. As shown in Figure 2A flow cytometric analysis of the vesicles derived from the T cell fraction revealed binding of annexin V-FITC and this signal was strongly enhanced after stimulation of vesicle blebbing. A comparative dot plot of lymphocyte membrane vesicles and fluorescent Megamix beads affirmed that the annexin V-positive vesicles were in the microparticle size gate (Fig. 2B). For quantification of the microparticle count, 5000 Trucount® beads were counted in a defined area and compared with the absolute number of microparticles in the microparticle gate. Non-stimulated lymphocytes showed a basic shedding of 4246 ± 1114 microparticles and this was significantly enhanced to 38,095 ± 9857 by the activation of T cells (P ≤ 0.001, Fig. 2C and D). The enrichment of the microparticle fraction could also be demonstrated by immunoblot analysis revealing the increased expression of LFA-1 (Fig. 2E). To exclude that any kind of cell death contributes to the Ca²⁺/A23187-induced release of microvesicles we measured the amount of live and dead cells by trypan blue staining and also the release of LDH from T cells. As shown in Figure 2F and G there was no significant difference with regard to both parameters in the cells treated with and without Ca²⁺/A23187 stimulation.
Analysis of proteasomes of microparticles shed by T lymphocytes

To investigate whether the microparticles may be a source of extracellular proteasomes, we extracted their proteins by repeated freeze-thaw cycles. After centrifugation 20S proteasomes were detected in the supernatant fraction and quantified by ELISA (Fig. 3A). The microparticle fraction of resting 5 × 10⁶ lymphocytes contained 4 ± 1 ng 20S proteasomes, whereas the same amount of A23187/CaCl₂ treated T cells contained 28 ± 3 ng 20S proteasome (corresponding to 4246 ± 1114 versus 38,095 ± 9857 microparticles measured in Fig. 2D). To study whether the extracellular proteasomes are proteolytically active native gel electrophoresis was performed to separate the different proteasome complexes of microparticles and of T cell lysates. As a control we used purified human erythrocyte 26S proteasome.
Figure 3B shows the in-gel (substrate overlay technique) trypsin-like activity of proteasomal complexes after their separation by native gel electrophoresis. T cell lysates contain two proteolytically active complexes. As evidenced by immunoblotting with antibodies to subunit α6 (20S proteasome), to Rpt3 (19S regulator) and to PA28 (PA28β), the bigger of the two complexes contains the 19S regulator and PA28 in addition to the 20S proteasome. Thus, hybrid proteasome (19S-20S-PA28) is the predominant proteasome complex in T lymphocytes. The other proteolytically active complex in T cell lysates exhibits an electrophoretic mobility slightly slower than that of the 20S proteasome and represents 20S-PA28 proteasome complexes as shown by immune reactivity against the proteasome subunits α6 and PA28β. In contrast microparticles contain just protelytically active 20S proteasome (Fig. 3C).

Immunoblotting confirmed that proteasomes in microparticles are immunoproteasomes containing the subunits β5i/LMP2 and β5i/LMP7. As reflected by an enhanced signal for β5i/LMP2, β5i/LMP7 and LFA-1 activation of T cells by the calcium ionophore A23187 and CaCl2 results in increased generation of microparticles (Figs 2E and 4A). On the other hand, inhibition of microparticle blebbing by EGTA resulted in a strong reduction of microparticle derived 20S proteasomes (Fig. 4C). Notably, the Ca/A23187 enhanced packaging of T cell 20S proteasomes into microparticles seems to go along with an export of proteasomal regulatory complex subunits (Fig. 4B), which are not associated with the 20S core complex (compare Fig. 3B and C), because only under this experimental condition the 19S regulator subunit Rpt3 and PA28 were detectable.

**Microvesicles from human blood plasma contain proteasomes**

Since proteasomes are released from cells by microvesicle shedding, we were interested to know whether proteasome-containing microvesicles can also be isolated from blood plasma of human volunteers. In preceding experiments we had found that the concentration of circulating proteasomes in plasma was higher when the plasma probes were stored frozen before the ELISA was carried out (239 ± 138 ng/ml frozen versus 148 ± 132 ng/ml unfrozen). The proteasome concentrations measured in frozen and unfrozen platelet free plasma were 140 ± 118 ng/ml versus 140 ± 114 ng/ml, respectively. Therefore, platelets were removed from the plasma of six healthy donors before centrifugation. As shown by immunoblotting microvesicles of all individuals contained 20S proteasomes (Fig. 3S1). Their mean concentration was 14.8 ± 3.8 ng 20S proteasome/ml plasma. Analysis of the remaining supernatant fraction revealed that in all samples proteasomes were also present in a vesicle-free form, the mean concentration of which was 164 ng/ml (range 80–475 ng/ml). Thus, the ratio of microparticle bound to free 20S proteasome is about 1:11 suggesting that in plasma a mechanism must exist allowing the release of proteasomes from microvesicular structures.

**Microparticle breakdown by lipases releases free extracellular proteasomes**

The levels of lipid-degrading enzymes such as secretory phospholipase A2 (sPLA2) and sphingomyelinase (SMase) are known to be
increased in the blood plasma of patients suffering from several types of disorders [30–33]. Fourcade and co-workers reported that the combined action of sPLA2 and SMase released free fatty acids from vesicle membranes [26]. Therefore, we investigated whether of a commercially available SMase might hydrolyse microparticle membranes resulting in the release of proteasomes from microvesicles. Figure 5A shows that the amount of proteasome indicated by subunit α6 (detection of subunit LMP7 showed the same results; data not shown) and of the cell surface protein LFA-1 was significantly reduced in the vesicle fraction treated with SMase when compared to control samples. Accordingly, the proteasome content in the supernatant fractions of the SMase digestion samples was significantly increased and the liberation of proteasomes from vesicular structures by SMase appeared to be more efficient than repeated freeze-thaw cycles (compare Figs 5B and 3A). These data show that

Fig. 4 Detection of proteasomal subunits in microparticles. T lymphocyte microparticle fractions isolated from cell culture supernatants of control cells (MP DMSO), cells stimulated with 1 mM CaCl2 (MP Ca/DMSO) and cells treated with 1 mM CaCl2 and 2 μM A23187 (MP Ca/A23187) were subjected to SDS-PAGE and immunoblot analysis. Controls were human 20S immunoproteasomes (i20S), standard 20S (s20S) and 26S proteasomes (s26S) as well as PA28. (A) The MP fractions were analysed for proteasomal subunits α6, β1, β5, LMP2 and LMP7. (B) Proteins on immunoblots of controls and MPs were detected by antibodies for Rpt3 as well as PA28 α and β. (C) MP shedding was inhibited by depletion of Ca2+ with EGTA tracked by the detection of the α6 subunit.

Fig. 5 Turnover of microparticles with sphingomyelinase. (A) An aliquot of microparticles (MPs) from A23187-stimulated T lymphocytes, was used as a loading control for SDS-PAGE (lane 1a, 1b). A second aliquot was used for an in vitro degradation assay of the MPs by treatment (+) or non-treatment (−) with bacterial sphingomyelinase (SMase) at 37°C. The remaining lipid fraction was pelleted by centrifugation and dissolved by freeze-thaw cycles. Both membrane fractions were subjected to SDS-PAGE and analysed for their content of LFA-1 and proteasome subunit α6 (lane 2a, 2b). A quantitative evaluation of the band intensities was performed with Image J. (B) The supernatants of the microparticle SMase digestion as described in (A) were used for determination of liberated proteasomes. Mean values ± SEM (n = 4) are shown and the P-value were calculated by the Mann–Whitney Rank Sum test, *P = 0.029.
microparticles can be dismantled by sphingolipid hydrolysing enzymes resulting in the release of free proteasomes into the environment.

**Discussion**

Since proteasomes were detected to circulate in blood plasma and their concentration is increased in patients with various malignancies, the question arose whether circulating proteasomes are released from damaged cells. Although initially a positive correlation between the elevated serum proteasome levels and a marker for cell death, like LDH, was observed in patients with malignant neoplasms and some autoimmune diseases [5, 13] most other investigations in patients suffering from malignant and non-malignant diseases [11, 34–36] found only poor correlations between markers of cell lysis and the level of circulating proteasomes. Therefore, processes other than cell disruption may contribute to the level of circulating proteasomes and we show here that T lymphocytes traffic proteasomes into their environment packed in microparticles (Figs 1D, 4A and B). This mechanism is used for basal as well as for enhanced outward transfer, since a rise in proteasome-containing microparticle release was observed in the presence of Ca\(^{2+}\) and a Ca-ionophore (Figs 2 and 4). Since many different stimuli for the activation of cells are responsible for microparticle release like the early phase of apoptosis, Ca\(^{2+}\)-ions, phospholipase C, complement factor C5a, C-reactive protein and high concentrations of ATP [16, 37], it is not surprising that several diseases linked to a misguided immune response like SLE, polymyositis, primary Sjögren’s syndrome, sepsis and RA as well as hematologic malignancies and other forms of cancer go along with increased levels of serum microparticles and circulating proteasomes (Table S1).

Calculating the proteasome content in microparticles shed from cultured T cells (Figs 1 and 2) yields about 1 ng proteasome/1000–1300 microparticles. Since the number of microparticles in healthy individuals vary between 10\(^2\) and 10\(^3\)/ml blood [38], a quantitative release of their content into plasma would result in a concentration of 10–1000 ng proteasome/ml plasma. Considering that plasma microparticles are thought to have various cellular origins including platelets, erythrocytes, leukocytes, endothelial cells and vascular smooth muscle cells [37], 400 ng circulating proteasomes/ml plasma as measured in normal individuals [15] fits well to our experimental findings.

Since circulating proteasomes in patients were directly quantified by ELISA technique, they must exist in a free, non-vesicular form, allowing binding of antibodies for reproducible quantification. Applying an in-vitro assay it was shown that two phosphodiesterases, cPLA2 and SMase, catalyse microparticle membrane turnover [26] and thus may release the vesicle content including proteasomes into body fluids. Our experiments using a commercially available bacterial SMase led to pronounced microparticle degradation and to liberation of vesicular proteasomes (Fig. 5) and thus sustain the likelihood of this mechanism to be physiologically relevant. Proinflammatory mediators foster the release of lipid-degrading enzymes, as sPLA2 was found to be released from rat calvarial bone-forming cells by IL-1 and TNF-\(\alpha\) influence [39]. Acid-SMase was reported to be secreted by endothelial cells by cytokine activation including interferon-\(\gamma\) and IL-1\(\beta\) [40], suggesting a pathophysiological relevance for these phospholipases. Elevated plasma levels of lipid-hydrolyzing enzymes have been linked to various disorders like rheumatoid arthritis (sPLA2) and sepsis (sPLA2, acid-SMase) [31, 41, 42] that are also characterized by increased levels of extracellular proteasomes [15]. Since, the levels of microparticles were inversely correlated with sPLA2 activity [43], elevated levels of extracellular proteasomes are a reasonable consequence. Therefore, our in-vitro experiments may indeed mimic the in vivo situation.

Our data are compatible with proteomic analyses of microparticles, which identified subunits of proteasomes and their regulators in platelet and T lymphocyte microvesicles [23, 24]. Moreover, our data show that proteasomes released from microparticles are proteolytically active. Whether proteasomes exhibit any proteolytic function in the extracellular environment remains unknown and is a matter of debate [14, 15]. Recently, Lai and colleagues detected that exosomes deriving from the endosomal compartment of mesenchymal stem cells also contain proteolytically active 20S proteasomes and they proposed that exosomal proteasomes may have a cardioprotective effect [44]. On the other hand, microparticles as well as exosomes may be a potent source for autoantigens and provoke an immune response, because autoantibodies to proteasomal subunits were found only poor correlations between markers of cell lysis and the level of circulating proteasomes and we show here that T lymphocytes traffic proteasomes into their environment packed in microparticles (Figs 1D, 4A and B). This mechanism is used for basal as well as for enhanced outward transfer, since a rise in proteasome-containing microparticle release was observed in the presence of Ca\(^{2+}\) and a Ca-ionophore (Figs 2 and 4). Since many different stimuli for the activation of cells are responsible for microparticle release like the early phase of apoptosis, Ca\(^{2+}\)-ions, phospholipase C, complement factor C5a, C-reactive protein and high concentrations of ATP [16, 37], it is not surprising that several diseases linked to a misguided immune response like SLE, polymyositis, primary Sjögren’s syndrome, sepsis and RA as well as hematologic malignancies and other forms of cancer go along with increased levels of serum microparticles and circulating proteasomes (Table S1).

Calculating the proteasome content in microparticles shed from cultured T cells (Figs 1 and 2) yields about 1 ng proteasome/1000–1300 microparticles. Since the number of microparticles in healthy individuals vary between 10\(^2\) and 10\(^3\)/ml blood [38], a quantitative release of their content into plasma would result in a concentration of 10–1000 ng proteasome/ml plasma. Considering that plasma microparticles are thought to have various cellular origins including platelets, erythrocytes, leukocytes, endothelial cells and vascular smooth muscle cells [37], 400 ng circulating proteasomes/ml plasma as measured in normal individuals [15] fits well to our experimental findings.

Since circulating proteasomes in patients were directly quantified by ELISA technique, they must exist in a free, non-vesicular form, allowing binding of antibodies for reproducible quantification. Applying an in-vitro assay it was shown that two phosphodiesterases, cPLA2 and SMase, catalyse microparticle membrane turnover [26] and thus may release the vesicle content including proteasomes into body fluids. Our experiments using a commercially available bacterial SMase led to pronounced microparticle degradation and to liberation of vesicular proteasomes (Fig. 5) and thus sustain the likelihood of this mechanism to be physiologically relevant. Proinflammatory mediators foster the release of lipid-degrading enzymes, as sPLA2 was found to be released from rat calvarial bone-forming cells by IL-1 and TNF-\(\alpha\) influence [39]. Acid-SMase was reported to be secreted by endothelial cells by cytokine activation including interferon-\(\gamma\) and IL-1\(\beta\) [40], suggesting a pathophysiological relevance for these phospholipases. Elevated plasma levels of lipid-hydrolyzing enzymes have been linked to various disorders like rheumatoid arthritis (sPLA2) and sepsis (sPLA2, acid-SMase) [31, 41, 42] that are also characterized by increased levels of extracellular proteasomes [15]. Since, the levels of microparticles were inversely correlated with sPLA2 activity [43], elevated levels of extracellular proteasomes are a reasonable consequence. Therefore, our in-vitro experiments may indeed mimic the in vivo situation.

Our data are compatible with proteomic analyses of microparticles, which identified subunits of proteasomes and their regulators in platelet and T lymphocyte microvesicles [23, 24]. Moreover, our data show that proteasomes released from microparticles are proteolytically active. Whether proteasomes exhibit any proteolytic function in the extracellular environment remains unknown and is a matter of debate [14, 15]. Recently, Lai and colleagues detected that exosomes deriving from the endosomal compartment of mesenchymal stem cells also contain proteolytically active 20S proteasomes and they proposed that exosomal proteasomes may have a cardioprotective effect [44]. On the other hand, microparticles as well as exosomes may be a potent source for autoantigens and provoke an immune response, because autoantibodies to proteasomal subunits were detected in the plasma of individuals with autoimmune disorders [45, 46].

In summary, the data presented here provide a novel link between microparticle shedding and extracellular proteasomes and will require further investigations on microparticle count, plasma phospholipase activity and level of circulating proteasomes in healthy and diseased volunteers to evaluate the impact of this system on disease activity and prognostic value.

**Acknowledgements**

The authors kindly thank Alexander Kloß, Richard Golnik and Dr. Andreas Klein for technical support.

**Conflicts of interest**

The authors confirm that there are no conflicts of interest.

**Supporting information**

Additional Supporting Information may be found in the online version of this article:

**Figure S1** Analysis of vesicle-associated proteasomes in plasma of healthy individuals.

**Table S1** Different pathophysiological states are associated with heightened levels of circulating proteasomes and microparticles.
References

1. Majetschak M, Perez M, Sorell LT, et al. Circulating 20S proteasome levels in patients with mixed connective tissue disease and systemic lupus erythematosus. *Clin Vaccine Immunol.* 2008; 15: 1489–93.

2. Henry L, Lavabre-Bertrand T, Douché T, et al. Diagnostic value and prognostic significance of plasmatic proteasome level in patients with melanoma. *Exp Dermatol.* 2010; 19: 1054–9.

3. Jakob C, Egerer K, Liebisch P, et al. Circulating proteasome levels are an independent prognostic factor for survival in multiple myeloma. *Blood.* 2007; 109: 2105–5.

4. Heubner M, Wimberger P, Dahlmann B, et al. The prognostic impact of circulating proteasome concentrations in patients with epithelial ovarian cancer. *Gynecol Oncol.* 2011; 120: 233–8.

5. Wada M, Kosaka M, Saito S, et al. Serum concentration and localization in tumor cells of proteasomes in patients with hematologic malignancy and their pathophysiologic significance. *J Lab Clin Med.* 1993; 121: 215–23.

6. Henry L, Lavabre-Bertrand T, Vercambre L, et al. Plasma proteasome level is a reliable early marker of malignant transformation of liver cirrhosis. *Gut.* 2009; 58: 833–8.

7. Coux O, Tanaka K, Goldberg AL. Structure and functions of the 20S and 26S proteasomes. *Annu Rev Biochem.* 1996; 65: 801–47.

8. Kruger E, Kloetzl PM. Immunoproteasomes at the interface of innate and adaptive immune responses: two faces of one enzyme. *Curr Opin Immunol.* 2012; 24: 77–83.

9. Ebstein F, Kloetzl PM, Kruger E, et al. Emerging roles of immunoproteasomes beyond MHC class I antigen processing. *Cell Mol Life Sci.* 2012; 69: 2543–58.

10. Zoeger A, Blau M, Egerer K, et al. Circulating proteasomes are functional and have a subtype pattern distinct from 20S proteasomes in major blood cells. *Clin Chem.* 2006; 52: 2079–86.

11. Sixt SU, Adamzik M, Spyrya D, et al. Alveolar extracellular 20S proteasomes in patients with acute respiratory distress syndrome. *Am J Respir Crit Care Med.* 2009; 179: 1098–106.

12. Mueller O, Anlasik T, Wiedemann J, et al. Circulating extracellular proteasome in the cerebrospinal fluid: a study on concentration and proteolytic activity. *J Mol Neurosci.* 2011; 46: 509–15.

13. Egerer K, Kuckelkorn U, Rudolph PE, et al. Circulating proteasomes are markers of cell damage and immunologic activity in autoimmune diseases. *J Rheumatol.* 2002; 29: 2045–52.

14. Sixt SU, Peters J. Extracellular alveolar proteasome: possible role in lung injury and repair. *Proc Am Thorac Soc.* 2010; 7: 91–6.

15. Sixt SU, Dahlmann B. Extracellular, circulating proteasomes and ubiquitin - incidence and relevance. *Biochim Biophys Acta.* 2008; 1782: 617–23.

16. Cecchi E, Racchetti G, Meldolesi J. Shedding microvesicles: artefacts no more. *Trends Cell Biol.* 2009; 19: 43–51.

17. Nickel W. Unconventional secretory routes: direct protein export across the plasma membrane of mammalian cells. *Traffic.* 2005; 6: 607–14.

18. Mause SF, Weber C. Microparticles: protagonists of a novel communication network for intercellular information exchange. *Circ Res.* 2010; 107: 1047–57.

19. Mack M, Kleinschmidt A, Bruhl H, et al. Transfer of the chemokine receptor CCR5 between cells by membrane-derived microparticles: a mechanism for cellular human immunodeficiency virus 1 infection. *Nat Med.* 2000; 6: 789–79.

20. MacKenzie A, Wilson HL, Kiss-Toth E, et al. Rapid secretion of interleukin-1beta by microvesicle shedding. *Immunity.* 2001; 15: 825–35.

21. Yuan A, Farber EL, Rapoport AL, et al. Transfer of microRNAs by embryonic stem cell microvesicles. *PLoS ONE.* 2009; 4: e4722.

22. Tang K, Liu J, Yang Z, et al. Microparticles mediate enzyme transfer from platelets to mast cells: a new pathway for lipoxin A4 biosynthesis. *Biochem Biophys Res Commun.* 2010; 400: 432–6.

23. Garcia BA, Smalley DM, Cho H, et al. The platelet microparticle proteome. *J Proteome Res.* 2005; 4: 1516–21.

24. Miguel L, Faceda K, Felden C, et al. Proteomic analysis of malignant lymphocyte membrane microparticles using double iGonization coverage optimization. *Proteomics.* 2006; 6: 153–71.

25. Kopp F, Dahlmann B, Kuehn L. Reconstitution of hybrid proteasomes from purified PA700-20 S complexes and PA28Alphabeta activator: ultrastructure and peptidase activities. *J Mol Biol.* 2001; 313: 465–71.

26. Fourcade Q, Simon MF, Viode C, et al. Secretory phospholipase A2 generates the novel lipid mediator lysosphosphatidic acid in membrane microvesicles shed from activated cells. *Cell.* 1995; 80: 919–27.

27. Mobarrez F, Antovic J, Egberg N, et al. A multicolor flow cytometric assay for measurement of platelet-derived microparticles. *Thromb Res.* 2010; 125: e110–6.

28. McVey M, Tabuchi A, Kuebler WM. Microparticles and acute lung injury. *Am J Physiol Lung Cell Mol Physiol.* 2012; 303: L364–81.

29. Gelderman MP, Simak J. Flow cytometric analysis of cell membrane microparticles. *Methods Mol Biol.* 2008; 484: 79–93.

30. Doeherw N, Bunck AC, Rauhaus M, et al. Secretory sphingomyelinase is upregulated in chronic heart failure: a second messenger system of immune activation relates to body composition, muscular functional capacity, and peripheral blood flow. *Eur Heart J.* 2007; 28: 821–8.

31. Claus RA, Bunck AC, Bockmeyer CL, et al. Role of increased sphingomyelinase activity in apoptosis and organ failure of patients with severe sepsis. *FASEB J.* 2005; 19: 1719–21.

32. Gorska M, Baranczuk E, Dobrznyn A. Secretory Zn2+ -dependent sphingomyelinase activity in the serum of patients with type 2 diabetes is elevated. *Horm Metab Res.* 2003; 35: 506–7.

33. Pruzanski W, Vadas P, Stefanaki E, et al. Phospholipase A2 activity in sera and synovial fluids in rheumatoid arthritis and osteoarthritis. Its possible role as a proinflammatory enzyme. *J Rheumatol.* 1985; 12: 211–6.

34. Roth GA, Moser B, Krenn C, et al. Heightened levels of circulating 20S proteasome in critically ill patients. *Eur J Clin Invest.* 2005; 35: 399–403.

35. Lavabre-Bertrand T, Henry L, Carillo S, et al. Plasma proteasome level is a potential marker in patients with solid tumors and hematologic malignancies. *Cancer.* 2001; 92: 2493–500.

36. Stoebner PE, Lavabre-Bertrand T, Henry L, et al. High plasma proteasome levels are detected in patients with metastatic malignant melanoma. *Br J Dermatol.* 2005; 152: 448–53.

37. Distler JH, Psistky DS, Huber LC, et al. Microparticles as regulators of inflammation: novel players of cellular crosstalk in the rheumatic diseases. *Arthritis Rheum.* 2005; 52: 3337–48.

38. Antwi-Baffour S, Khola S, Aryee YK, et al. Human plasma membrane-derived vesicles inhibit the phagocytosis of apoptotic cells—
possible role in SLE. *Biochem Biophys Res Commun.* 2010; 398: 278–83.

39. Vadas P, Pruzanski W, Stefanski E, *et al.* Extracellular phospholipase A2 secretion is a common effector pathway of interleukin-1 and tumour necrosis factor action. *Immunol Lett.* 1991; 28: 187–93.

40. Marathe S, Schissel SL, Yellin MJ, *et al.* Human vascular endothelial cells are a rich and regulatable source of secretory sphingomyelinase. Implications for early atherogenesis and ceramide-mediated cell signaling. *J Biol Chem.* 1998; 273: 4081–8.

41. Lin MK, Farewell V, Vadas P, *et al.* Secretory phospholipase A2 as an index of disease activity in rheumatoid arthritis. Prospective double blind study of 212 patients. *J Rheumatol.* 1996; 23: 1162–6.

42. Green JA, Smith GM, Buchta R, *et al.* Circulating phospholipase A2 activity associated with sepsis and septic shock is indistinguishable from that associated with rheumatoid arthritis. *Inflammation.* 1991; 15: 355–67.

43. Sellam J, Proulle V, Jungel A, *et al.* Increased levels of circulating microparticles in primary Sjogren’s syndrome, systemic lupus erythematosus and rheumatoid arthritis and relation with disease activity. *Arthritis Res Ther.* 2009; 11: R156.

44. Lai RC, Tan SS, Teh BJ, *et al.* Proteolytic potential of the MSC exosome proteome: implications for an exosome-mediated delivery of therapeutic proteasome. *Int J Proteomics.* 2012; 2012: 971907.

45. Feist E, Dorner T, Kuckelkorn U, *et al.* Diagnostic importance of anti-proteasome antibodies. *Int Arch Allergy Immunol.* 2000; 123: 92–7.

46. Scheffler S, Kuckelkorn U, Egerer K, *et al.* Autoimmune reactivity against the 20S-proteasome includes immunosubunits LMP2 (beta1i), MECL1 (beta2i) and LMP7 (beta5i). *Rheumatology.* 2008; 47: 622–6.